BioCentury
ARTICLE | Company News

Alexion gets fast track for complement inhibitor

February 29, 2000 8:00 AM UTC

ALXN received fast track status from the FDA for its humanized monoclonal antibody C5 complement inhibitor 5G1.1 to treat patients with membranous glomerulonephritis. The compound is in Phase II trial...